Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis

Zhang,Bo; Hu,Mintao; Huang,Lihua; Pu,Yunchuan; Pei,Hao; Hua,Zhong; Yao,Shangzhi

doi:10.3892/etm.2014.1891

October 2014 Volume 8 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2014 Volume 8 Issue 4

Full Size Image

Article

Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis

Authors:
- Bo Zhang
- Mintao Hu
- Lihua Huang
- Yunchuan Pu
- Hao Pei
- Zhong Hua
- Shangzhi Yao
View Affiliations / Copyright

Affiliations: Department of Infectious Diseases, The Fifth People's Hospital of Wuxi, Wuxi, Jiangsu 214005, P.R. China
Pages: 1123-1126
|
Published online on: August 8, 2014

https://doi.org/10.3892/etm.2014.1891
Expand metrics +

Abstract

The aim of the present study was to observe the effects of Fuzheng Huayu capsule combined with Pegasys (peginterferon α‑2a) on hepatic fibrosis in rats and in the treatment of patients with genotype 1 hepatitis C and hepatic cirrhosis. A dimethylnitrosamine (DMN)‑induced rat model of liver injury was established. Fuzheng Huayu capsule combined with Pegasys was administered to the rats and the DMN‑induced hepatocyte apoptosis was observed. In addition, a total of 100 patients with genotype 1 hepatitis C and hepatic cirrhosis were treated by oral administration of Fuzheng Huayu capsule combined with Pegasys or with Pegasys alone. The therapeutic effect of Fuzheng Huayu capsule combined with Pegasys was analyzed. Following the oral administration of Fuzheng Huayu capsule combined with Pegasys to the DMN model rats, the expression of α‑smooth muscle actin was found to be significantly reduced, hemopoietic stem cell apoptosis was increased and liver cell apoptosis was reduced. These indices were significantly different compared with those in the model group (P<0.05). Liver function and liver fibrosis were markedly recovered in hepatitis C patients with hepatic cirrhosis following treatment with the combination treatment compared with those in the patients treated with Pegasys alone (P<0.05). In conclusion, the combination of Fuzheng Huayu capsule with Pegasys inhibited liver fibrosis and cell apoptosis, and may be a novel therapeutic strategy for the treatment of patients with compensated cirrhosis due to hepatitis C. This study provides a method for the optimization of existing treatment strategies and for the establishment of potentially effective combination therapies.

View Figures

View References

1	Lavanchy D: The global burden of hepatitis C. Liver Int. 29(Suppl 1): 74–81. 2009. View Article : Google Scholar
2	Bota S, Sporea I, Popescu A, Sirli R, Neghina AM, Danila M and Strain M: Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review. J Gastrointestin Liver Dis. 20:293–298. 2011.PubMed/NCBI
3	Michielsen P, Ho E and Francque S: Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Minerva Gastroenterol Dietol. 58:65–79. 2012.PubMed/NCBI
4	Ghany MG, Strader DB, Thomas DL and Seeff LB: American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI
5	Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. McCaughan GW, Omata M, Amarapurkar D, et al: Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 22:615–633. 2007. View Article : Google Scholar
6	Guedj H, Guedj J, Negro F, et al: The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat. 19:488–496. 2012. View Article : Google Scholar : PubMed/NCBI
7	Heathcote EJ, Shiffman ML, Cooksley WG, et al: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 343:1673–1680. 2000. View Article : Google Scholar : PubMed/NCBI
8	Gordon SC: Treatment of viral hepatitis-2001. Ann Med. 33:385–390. 2001. View Article : Google Scholar : PubMed/NCBI
9	Wu JW and Wang W: The relationship of rat fibrosis and hyaluronic acid and related proteins. Chinese Journal of Anatomy. 23:2682010.(In Chinese).
10	Cui AL: Treatment of 54 cases of active hepatocirrhosis with lamivudine combined with Fu Zheng Hua Yu capsule. Journal of China Pharmaceutical. 21:74–75. 2012.(In Chinese).
11	De Bleser PJ, Niki T, Xu G, Rogiers V and Geerts A: Localization and cellular sources of activins in normal and fibrotic rat liver. Hepatology. 26:905–912. 1997.PubMed/NCBI
12	Brenndörfer ED, Weiland M, Frelin L, et al: Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology. 52:1553–1563. 2010.
13	Tan CY, Tan SZ, Jiang J and Xu LM: Effects of ‘Fuzheng Huayu Decoction’ on hepatocellular apoptosis in rats with DMN liver fibrosis. Shanghai Journal of Traditional Chinese Medicine. 39:47–49. 2005.(In Chinese).
14	Prati GM, Aghemo A, Rumi MG, et al: Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol. 56:341–347. 2012.PubMed/NCBI
15	Bzowej N, Nelson DR, Terrault NA, et al: PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 17:528–538. 2011. View Article : Google Scholar : PubMed/NCBI
16	Park CH, Kim DH, Park MH, et al: Chinese prescription Kangen-karyu and Salviae Miltiorrhizae radix improve age-related oxidative stress and inflammatory response through the PI3K/Akt or MAPK pathways. Am J Chin Med. 42:987–1005. 2014.
17	Teng H and Lee WY: Antibacterial and antioxidant activities and chemical compositions of volatile oils extracted from Schisandra chinensis Baill. seeds using simultaneous distillation extraction method, and comparison with Soxhlet and microwave-assisted extraction. Biosci Biotechnol Biochem. 78:79–85. 2014.PubMed/NCBI
18	Yu HY, Chen ZY, Sun B, et al: Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties. J Nat Prod. 77:1311–1320. 2014.
19	Cheng N, Ren N, Gao H, Lei X, Zheng J and Cao W: Antioxidant and hepatoprotective effects of Schisandra chinensis pollen extract on CCl4-induced acute liver damage in mice. Food Chem Toxicol. 55:234–240. 2013. View Article : Google Scholar : PubMed/NCBI
20	Li TF, Qin MZ and Hu SS: The expression of Fas and FasL in PBMC of multiple sclerosis patients. Shanghai Journal of Immunology. 22:1312002.(In Chinese).
21	Alkahtani S: Hepatitis C infection and apoptosis in hepatocellular carcinoma. Pak J Biol Sci. 12:804–808. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zaki Mel S, Auf FA, Ghawalby NA and Saddal NM: Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C. Immunol Invest. 37:163–170. 2008.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis

This article is mentioned in:

Abstract

Figure 1

Related Articles